Business Description
CSL Ltd
ISIN : AU000000CSL8
Share Class Description:
MEX:CSL: Ordinary SharesCompare
Compare
Traded in other countries / regions
CSL.AustraliaCSLLY.USACSJ.GermanyCSL.Mexico IPO Date
2019-06-18Description
CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.14 | |||||
| Equity-to-Asset | 0.46 | |||||
| Debt-to-Equity | 0.7 | |||||
| Debt-to-EBITDA | 2.59 | |||||
| Interest Coverage | 6.57 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 4.36 | |||||
| Beneish M-Score | -2.17 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 15.7 | |||||
| 3-Year EBITDA Growth Rate | 12.2 | |||||
| 3-Year EPS without NRI Growth Rate | 6.4 | |||||
| 3-Year FCF Growth Rate | -5.9 | |||||
| 3-Year Book Growth Rate | 31 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 18.56 | |||||
| Future 3-5Y Total Revenue Growth Rate | 7.69 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.18 | |||||
| Quick Ratio | 0.97 | |||||
| Cash Ratio | 0.33 | |||||
| Days Inventory | 289.52 | |||||
| Days Sales Outstanding | 57.73 | |||||
| Days Payable | 78.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Dividend Growth Rate | 10.7 | |||||
| 3-Year Average Share Buyback Ratio | -2 | |||||
| Shareholder Yield % | 1.29 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 51.47 | |||||
| Operating Margin % | 18.79 | |||||
| Net Margin % | 17.96 | |||||
| FCF Margin % | 10.42 | |||||
| ROE % | 15.75 | |||||
| ROA % | 7.11 | |||||
| ROIC % | 6.8 | |||||
| ROC (Joel Greenblatt) % | 26.72 | |||||
| ROCE % | 11.71 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 33.95 | |||||
| Forward PE Ratio | 25.93 | |||||
| PE Ratio without NRI | 33.95 | |||||
| Shiller PE Ratio | 41.85 | |||||
| Price-to-Owner-Earnings | 33.45 | |||||
| PEG Ratio | 3.9 | |||||
| PS Ratio | 6.1 | |||||
| PB Ratio | 5.12 | |||||
| Price-to-Tangible-Book | 87.39 | |||||
| Price-to-Free-Cash-Flow | 59.33 | |||||
| Price-to-Operating-Cash-Flow | 32.36 | |||||
| EV-to-EBIT | 27.07 | |||||
| EV-to-Forward-EBIT | 20.85 | |||||
| EV-to-EBITDA | 21.69 | |||||
| EV-to-Forward-EBITDA | 18.51 | |||||
| EV-to-Revenue | 6.99 | |||||
| EV-to-Forward-Revenue | 7.97 | |||||
| EV-to-FCF | 66.42 | |||||
| Price-to-Projected-FCF | 3.06 | |||||
| Price-to-DCF (Earnings Based) | 2.13 | |||||
| Price-to-DCF (FCF Based) | 3.79 | |||||
| Price-to-Median-PS-Value | 0.72 | |||||
| Price-to-Peter-Lynch-Fair-Value | 3.89 | |||||
| Price-to-Graham-Number | 11.48 | |||||
| Earnings Yield (Greenblatt) % | 3.68 | |||||
| FCF Yield % | 1.64 | |||||
| Forward Rate of Return (Yacktman) % | 10 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CSL Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 259,459.847 | ||
| EPS (TTM) (MXN) | 95.233 | ||
| Beta | -0.02 | ||
| Volatility % | 0.92 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (MXN) | 0 | ||
| 20-Day SMA (MXN) | 3635.42 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (MXN) | 3635.42 - 3635.42 | ||
| Shares Outstanding (Mil) | 484.21 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CSL Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CSL Ltd Stock Events
| Event | Date | Price(MXN) | ||
|---|---|---|---|---|
| No Event Data | ||||
CSL Ltd Frequently Asked Questions
What is CSL Ltd(MEX:CSL)'s stock price today?
The current price of MEX:CSL is MXN3635.42. The 52 week high of MEX:CSL is MXN3635.42 and 52 week low is MXN3635.42.
When is next earnings date of CSL Ltd(MEX:CSL)?
The next earnings date of CSL Ltd(MEX:CSL) is 2025-02-13 Est..
Does CSL Ltd(MEX:CSL) pay dividends? If so, how much?
CSL Ltd(MEX:CSL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers